Loading…
MaxCyte, Inc. is projected to rise to $1.11 by 2027, a +3% move from its current price of $1.08. MXCT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.04 | $1.08 | $1.12 | +0.05% |
| May 30 | $1.03 | $1.08 | $1.14 | +0.10% |
| May 31 | $1.01 | $1.08 | $1.15 | +0.15% |
| Jun 1 | $1.00 | $1.08 | $1.17 | +0.20% |
| Jun 2 | $0.9958 | $1.08 | $1.18 | +0.25% |
| Jun 3 | $0.9884 | $1.08 | $1.19 | +0.30% |
| Jun 4 | $0.9817 | $1.08 | $1.20 | +0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9817 | $1.08 | $1.20 | +0.36% |
| Week 2 | $0.9456 | $1.09 | $1.25 | +0.71% |
| Week 3 | $0.9196 | $1.09 | $1.30 | +1.07% |
| Week 4 | $0.8987 | $1.10 | $1.34 | +1.43% |
| Week 5 | $0.881 | $1.10 | $1.37 | +1.79% |
| Week 6 | $0.8657 | $1.10 | $1.41 | +2.15% |
| Week 7 | $0.852 | $1.11 | $1.44 | +2.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MaxCyte, Inc. is a healthcare company that discovers, develops, and commercializes cell therapeutics in the United States and internationally.
The company licenses and sells its instruments and technology, and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. Its product lineup includes ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, and expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
MaxCyte was incorporated in 1998 and is headquartered in Rockville, Maryland.
MXCT is the trading ticker for MaxCyte, Inc. It currently trades at $1.04 with a market cap of $111.41M and a rank of 4182.
The asset sits in the Healthcare category, and the price outlook is elevated by a multi-year forecast showing gradual upside from the current level toward higher averages in later years. The forecast projects the 2030 average near $1.07 and the 2040 average near $2.28, with the 2050 average near $2.99 and maximums climbing to $6.11 by 2050.
Near-term dynamics show a cautiously bullish path, with notable upside in the longer horizon as the forecast maxs increase to $4.20 in 2040 and $6.11 in 2050, accompanied by risingROI figures (e.g., 2032 at 39%, 2033 at 51.1%, 2040 at 119.3%, and 2050 at 187.4%).
A major floor 37.4% below — a decisive break under it would weaken the trend.
The nearest floor, 24.5% below — buyers have tended to step in here.
Price is pressing into resistance (0.9% away) — a breakout level to watch.
A major ceiling 17.6% above — clearing it would confirm fresh momentum.
Key MXCT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MXCT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.05 | Buy | $1.05 | Buy |
| MA 10 | $1.05 | Buy | $1.02 | Buy |
| MA 20 | $0.949 | Buy | $0.9722 | Buy |
| MA 50 | $0.8505 | Buy | $0.9165 | Buy |
| MA 100 | $0.9146 | Buy | $0.9984 | Buy |
| MA 200 | $1.23 | Sell | $1.33 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.04 | Neutral |
| Stoch RSI (14) | 65.01 | Neutral |
| CCI (20) | 86.47 | Neutral |
| Williams %R (14) | -3.66 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 28.11 | Buy |
| Bollinger %B (20,2) | 0.82 | Neutral |
| Stochastic %K (14) | 96.34 | Sell |
| TRIX (15) | 0.91 | Buy |
| Awesome (5,34) | 0.14 | Buy |
| Ultimate (7,14,28) | 62.63 | Neutral |
| Momentum (10) | 0.26 | Buy |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 1.04 | Buy |
| ADX (14) | 21.82 | Buy |
| ATR (14) | 0.04 | Info |
The 30-day technical picture shows a bullish sentiment with RSI14 at 60. The price is around $1.04, above the SMA50 of $0.8415 but below the SMA200 of $1.23.
Support is at $0.815 and resistance at $1.09. The 30-day price range spans from $0.8257 to $1.31, illustrating a trajectory that has recently found a floor near the $0.82 level and faces resistance near the $1.09 mark.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.676 | $1.08 | $1.38 | 0% | Neutral | |
| $0.8486 | $1.11 | $1.55 | +3% | Neutral | |
| $0.8553 | $1.16 | $1.71 | +8% | Neutral | |
| $0.7471 | $1.05 | $1.60 | -3% | Neutral | |
| $0.7688 | $1.11 | $1.75 | +3% | Neutral | |
| $0.8784 | $1.31 | $2.10 | +21% | Bullish | |
| $1.02 | $1.55 | $2.56 | +44% | Bullish | |
| $1.07 | $1.67 | $2.82 | +55% | Bullish | |
| $0.9877 | $1.58 | $2.71 | +46% | Bullish | |
| $0.9691 | $1.58 | $2.77 | +47% | Bullish | |
| $1.36 | $2.47 | $4.67 | +129% | Bullish | |
| $1.47 | $3.22 | $6.77 | +198% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.676 | $1.08 | $1.27 | +0.00% |
| June 2026 | $0.9159 | $1.08 | $1.32 | +0.40% |
| July 2026 | $0.9443 | $1.13 | $1.40 | +4.31% |
| August 2026 | $0.9266 | $1.12 | $1.41 | -0.97% |
| September 2026 | $0.8852 | $1.08 | $1.37 | -3.74% |
| October 2026 | $0.887 | $1.09 | $1.40 | +0.90% |
| November 2026 | $0.891 | $1.10 | $1.43 | +1.07% |
| December 2026 | $0.8519 | $1.06 | $1.38 | -3.83% |
Click any year to see its month-by-month MXCT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MXCT is projected to trade between $0.676 and $1.38, averaging $1.08 — a potential gain of 0% from today's $1.08. A consolidation phase looks the most probable path here.
MaxCyte, Inc.'s 2027 outlook centres on $1.11, within a $0.8486 to $1.55 range. That is up +3% on the projected 2026 average. That marks a +3% change versus current levels. Price action looks broadly range-bound.
By 2028, MXCT could reach as high as $1.71, with a base case around $1.16 and support toward $0.8553 — roughly +8% from $1.08. A consolidation phase looks the most probable path here.
Expect MXCT to range from $0.7471 to $1.60 through 2029. The $1.05 average target implies a -3% move from current prices. That is -10% versus the projected 2028 average. Price action looks broadly range-bound.
The MXCT price prediction for 2030 points to an average of $1.11 (low $0.7688, high $1.75) — a potential gain of +3% on today's $1.08. A consolidation phase looks the most probable path here.
In 2031, MXCT is projected to trade between $0.8784 and $2.10, averaging $1.31 — a potential gain of +21% from today's $1.08. That is up +17% on the projected 2030 average. Momentum favours further upside here.
MaxCyte, Inc.'s 2032 outlook centres on $1.55, within a $1.02 to $2.56 range. That is up +19% on the projected 2031 average. That marks a +44% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, MXCT could reach as high as $2.82, with a base case around $1.67 and support toward $1.07 — roughly +55% from $1.08. Momentum favours further upside here.
Expect MXCT to range from $0.9877 to $2.71 through 2034. The $1.58 average target implies a +46% move from current prices. That is -6% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The MXCT price prediction for 2035 points to an average of $1.58 (low $0.9691, high $2.77) — a potential gain of +47% on today's $1.08. Momentum favours further upside here.
In 2040, MXCT is projected to trade between $1.36 and $4.67, averaging $2.47 — a potential gain of +129% from today's $1.08. That is up +56% on the projected 2035 average. Buyers look set to stay in control over this stretch.
MaxCyte, Inc.'s 2050 outlook centres on $3.22, within a $1.47 to $6.77 range. That is up +30% on the projected 2040 average. That marks a +198% change versus current levels. Momentum favours further upside here.
Investing $1,000 in MXCT today (≈ 925.925926 MXCT) could be worth
$2,978.44
+$1,978.44 (+198%) by 2050 · US Dollar
Based on the average projected MXCT price of $3.22 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MXCTwould be worth at today's price.
$1,000 invested in MXCT on May 27, 2025 (≈ 420.168047 MXCT) would be worth
$453.78
-$546.22 (-54.6%) today · 0.45× · US Dollar
Based on a MXCT entry price of $2.38 vs. today's $1.08.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.07 | $1,009.35 | +0.9% |
| 1 month ago | $0.874 | $1,235.7 | +23.6% |
| 3 months ago | $0.793 | $1,361.92 | +36.2% |
| 6 months ago | $1.76 | $613.64 | -38.6% |
| 1 year ago | $2.38 | $453.78 | -54.6% |
| All time (4.8y) ago | $17 | $63.53 | -93.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MXCT forecast.
Our base-case forecast reaches $2.20 around 2040.
Implied market cap at $2.20: $235.67M
The multi-year forecast outlines a path of increasing value through the coming years. In 2030 the expected average price is $1.07 with a 2.8% ROI; by 2032 the forecast shows an average of $1.45 and a 39% ROI; 2033 is $1.57 with 51.1% ROI. The long-horizon outlook strengthens further, with 2040 averaging $2.28 and a 119.3% ROI, and 2050 averaging $2.99 with a 187.4% ROI.
Earlier years such as 2026 show an average of $1.04 with 0% ROI, and 2027–2029 depict modest to negative returns at times (e.g., 2029 with -3.7% ROI). The forecast sentiment shifts to BULLISH in the later years, reflecting stronger upside potential, but these are estimates and not guarantees. Investors should consider the uncertainty inherent in forward projections.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $1.07 with a minimum of $0.7512 and a maximum of $1.65; the ROI is 2.8%. The sentiment is NEUTRAL.
The forecast indicates positive upside in several future years, with an average price path rising from $1.04 in 2026 toward higher levels. Notable ROIs include 39% in 2032, 51.1% in 2033, 119.3% in 2040, and 187.4% in 2050, though some years show lower or negative ROIs. These are estimates, not guarantees.
The forecast maximum in 2040 is $4.20, with an average around $2.28 and a 119.3% ROI. The sentiment is BULLISH for that horizon.
Current price is $1.04 and market cap is $111.41M.
The 30-day range is from $0.8257 to $1.31.
MaxCyte, Inc. Community Discussion
0Share your MaxCyte, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.